Phase 1/2 study of treatment for spinal cord injury with autologous mononuclear cells derived from bone marrow - Phase 1/2 study of treatment for spinal cord injury with autologous mononuclear cells derived from bone marrow

Department of plastic surgery, Kitano hospital0 个研究点目标入组 10 人开始时间: 2012年3月29日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patient whose spinal cord is transected completely 2. Patient with central spinal cord injury 3. Patient whose SOFA score is more than 3 (at the time of registration) 4. Patient with hepatitis B, hepatitis C, HIV, ATL,or papovavirus B19 5. Patient with malignant tumor within 5 years before registration 6. Patient with myeloproliferative disease Patient with myelodysplastic syndrome Patient with ischemic heart disease, difficult to control Patient with autoimmune disease Patient with spinal canal stenosis Patient with motor paralysis in the extremities due to the dysfunction of central nervous system before spinal cord injury Patient with hepatic dysfunction Patient with renal failure Patient with psychological diseases, difficult to control 7. Patient with history of participation of other clinical researches within 6 months before registration Patient who is a participant in other studies 8. Patient who is pregnancy or suspicion of pregnancy 9. Patient who is judged to be inappropriate as a participant in this study by researchers

发起方

Department of plastic surgery, Kitano hospital